| EPANOVA in Crohn's Disease, Study 1 (NCT00613197) | Tillotts Pharma AG | 2003-01-01 |
| Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease (NCT00740103) | Ferring Pharmaceuticals | 2002-12-01 |
| Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED) (NCT00818272) | Merck Sharp & Dohme LLC | 2002-12-01 |
| Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo (NCT00739986) | Ferring Pharmaceuticals | 2002-10-01 |
| An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease (NCT00074542) | Tillotts Pharma AG | 2002-09-01 |
| Remission in Subjects With Crohn's Disease, Open Label Extension (NCT01070303) | Abbott | 2002-08-01 |
| Remission in Subjects With Crohn's Disease, 1 Year Phase (NCT00055497) | Abbott | 2002-08-01 |
| Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease (NCT00275418) | Bnai Zion Medical Center | 2002-07-01 |
| CP-461 for the Treatment of Crohn's Disease (NCT00042055) | Astellas Pharma Inc | 2002-07-01 |
| Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease (NCT00280956) | Biogen | 2002-07-01 |
| Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis (NCT00152841) | University Health Network, Toronto | 2002-06-01 |
| Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease (NCT00048295) | Ionis Pharmaceuticals, Inc. | 2002-05-01 |
| Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease (NCT00055367) | Biogen | 2002-04-01 |
| A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease (NCT00055523) | Abbott | 2002-04-01 |
| Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease (NCT00055536) | Biogen | 2002-04-01 |
| A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease (NCT00446433) | Celgene Corporation | 2002-03-01 |
| A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease (NCT00072943) | Facet Biotech | 2002-03-01 |
| Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease (NCT00032786) | Biogen | 2002-03-01 |
| Remicade® Crohn's Disease Registry Across Canada (Study P02793) (NCT00755937) | Merck Sharp & Dohme LLC | 2002-02-01 |
| Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine (NCT00946946) | Dr. Falk Pharma GmbH | 2002-02-01 |
| Multicenter Trial For Patients With Acute Crohn's Disease (NCT00035503) | Teva Branded Pharmaceutical Products R&D, Inc. | 2002-01-31 |
| Probiotics in GastroIntestinal Disorders (NCT00510978) | University College Cork | 2002-01-01 |
| Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease (NCT00032799) | Biogen | 2001-12-01 |
| Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease (NCT00304252) | EMD Serono | 2001-11-01 |
| Glucocorticoid-induced Osteopenia in Children (NCT00289328) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2001-11-01 |
| G-CSF to Treat Crohn's Disease (NCT00025805) | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-10-23 |
| Treatment With Lactobacillus Rhamnosus and Lactobacillus Acidophilus for Patients With Active Colonic Crohn's Disease. (NCT00374374) | Odense University Hospital | 2001-05-01 |
| Top Down Versus Step Up Strategies in Crohn's Disease (NCT00554710) | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | 2001-05-01 |
| Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease (NCT00278577) | Richard Burt, MD | 2001-04-01 |
| Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease (NCT00048113) | Ionis Pharmaceuticals, Inc. | 2001-01-10 |
| Monoclonal Antibody Treatment of Crohn's Disease (NCT00007163) | National Institute of Allergy and Infectious Diseases (NIAID) | 2000-12-01 |
| Clarithromycin in Active Crohn's Disease (NCT00269386) | Royal Liverpool University Hospital | 2000-04-01 |
| The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry (NCT00553176) | Janssen Biotech, Inc. | 1999-08-01 |
| Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease (NCT00004941) | FDA Office of Orphan Products Development | 1996-07-01 |
| Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease (NCT00004423) | University of Vermont | 1995-12-01 |
| Monroe County Inflammatory Bowel Disease (IBD) Registry (NCT01032525) | University of Rochester | 1981-01-01 |
| Drug-Disease Interaction in Crohn's Disease (NCT01261286) | University of Alberta | |
| Expanded Access to Risankizumab (NCT03914261) | AbbVie | |
| Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels (NCT01787786) | University of Western Ontario, Canada | |
| Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease (NCT01510431) | Mesoblast, Inc. | |
| Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy (NCT01144156) | Rabin Medical Center | |
| Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment. (NCT00252369) | Sheba Medical Center | |
| Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease (NCT01215890) | University of Alberta | |
| CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD) (NCT03559660) | UCB Biopharma SRL | |
| Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA (NCT06856135) | Takeda | |